- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06202612
A SHR0302 BA Study on Healthy Subjects
February 18, 2024 updated by: Jiangsu HengRui Medicine Co., Ltd.
A Bioavailability Study of SHR0302 Tablet in Healthy Subjects
The purpose of this study is to evaluate and compare the pharmacokinetics of SHR0302 two different kind tablets in Healthy subjects after administration two kind tablets (quick release tablets and sustained-release tablets).
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ainan Zhou
- Phone Number: 0518-823429738
- Email: ainan.zhou.az1@hengrui.com
Study Contact Backup
- Name: Sheng Feng, Ph.D.
- Phone Number: 0518-823429738
- Email: sheng.feng@hengrui.com
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Male or female healthy subjects aged 18 to 60 (including 18 and 60);
- Weigh at least 50 kg (for male) and 45 kg (for female), respectively, and have a body mass index (BMI) ≥ 19 and ≤26 kg/m2. BMI = weight (kg)/[height (m)]2;
- From the signing of the informed consent form until 6 months after the last administration, the subject (including partner) has no family planning and is willing to use the high-efficiency contraceptive measures specified in the plan;
- Sign the informed consent before the trial, and fully understand the content, process and possible adverse reactions of the trial. Must be able to communicate with the investigator, understand and comply with all study requirements.
Exclusion Criteria:
- Any clinical history of serious diseases or conditions that the researcher believes may affect the trial results, including but not limited to circulatory system, endocrine system, nervous system, digestive system, urinary system or blood, immune, mental and metabolic disease history;
- Those who have a history of tuberculosis within 6 months before signing the informed consent form; Or those who tested positive for T-spot test within the first 4 weeks of randomization;
- Individuals who have a history of smoking (average daily smoking>5 cigarettes) within the 3 months prior to signing the informed consent form, or who cannot stop using any tobacco products during the study period;
- Those who consume more than 25 g of alcohol per day on average within three months before signing the informed consent form (for example, 750 mL of beer, 250 mL of wine, or 50 mL of Baijiu), or cannot stop using any alcoholic products during the study period, or those who are positive in the alcohol breath test during screening;
- Drug abusers, or those who have tested positive for urinary drug abuse during screening, including: morphine, methamphetamine, ketamine, cocaine, ecstasy (dimethylenedioxoamphetamine), marijuana (tetrahydrocannabidiol acid);
- During the screening period, if the QTc of the ECG examination is greater than 450 ms or there are other clinically significant abnormalities determined by the researcher;
- Vital signs, physical examinations, laboratory tests, abdominal ultrasound or chest imaging examinations during the screening period indicate the presence of abnormalities that have been determined by the researchers to be clinically significant;
- Hepatitis B surface antigen (HBsAg) positive, or anti hepatitis C virus (HCV) antibody positive, or human immunodeficiency virus (HIV) antibody positive, or syphilis antibody positive;
- Within the first 7 days of randomization, any beverage or food containing grapefruit, grapefruit, strong tea, coffee, mangoes, etc. was consumed;
- Allergic constitution, or suspected allergy to any component of SHR0302 medication;
- Infections that require systemic antimicrobial therapy that occurred within the first 4 weeks of randomization (viral, bacterial, fungal, parasitic infections);
- Have used any prescription drugs, over-the-counter drugs, Chinese herbal medicines, or dietary supplements within the first two weeks of randomization;
- Systemic treatment with inhibitors or inducers of cytochrome P450 3A4 enzyme (CYP3A4) within the first 4 weeks of randomization (see Annex 2 for details);
- Individuals who participated in any drug clinical trial and took the investigational drug within the first three months of randomization (calculated from the last visit of the previous trial) (if the five half-lives of the investigational drug exceed three months, the time of the five half-lives shall prevail);
- Received BCG vaccine within the first 12 months of randomization; Or receive or be exposed to other live vaccines or attenuated live vaccines within the first three months of randomization; Or those who plan to receive the vaccine during the trial period;
- Individuals who have undergone any surgery within the first three months of randomization, or who have not yet recovered after surgery, or who are expected to have surgery or hospitalization plans during the trial period;
- Individuals who have donated (or lost) blood within the first three months of randomization and have donated (or lost) ≥ 400 mL of blood, or have received blood transfusions;
- According to the researcher's judgment, the subjects may have factors that affect drug absorption, distribution, metabolism, and excretion, or other factors that are not suitable for participation in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SHR0302 quick release tablet and sustained-release tablet
|
SHR0302 quick release tablets 8 mg
SHR0302 sustained-release tablets 10 mg
|
Experimental: SHR0302 sustained-release tablet and quick release tablet
|
SHR0302 quick release tablets 8 mg
SHR0302 sustained-release tablets 10 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PK parameters of SHR0302: Cmax
Time Frame: Based on pre-dose, 0.25-72 hours post-dose sampling times after administration on Day 1 and Day 5
|
Based on pre-dose, 0.25-72 hours post-dose sampling times after administration on Day 1 and Day 5
|
|
PK parameters of SHR0302: AUC0-t
Time Frame: Based on pre-dose, 0.25-72 hours post-dose sampling times after administration on Day1 and Day 5
|
Based on pre-dose, 0.25-72 hours post-dose sampling times after administration on Day1 and Day 5
|
|
PK parameters of SHR0302: AUC0-inf
Time Frame: Based on pre-dose, 0.25-72 hours post-dose sampling times after administration on Day 1 and Day 5
|
Based on pre-dose, 0.25-72 hours post-dose sampling times after administration on Day 1 and Day 5
|
|
Relative bioavailability (F%) between SHR0302 sustained-release tablets and SHR0302 rapid release tablets
Time Frame: Based on pre-dose, 0.25-72 hours post-dose sampling times after administration on Day 1 and Day 5
|
F%=AUC (sustained-release tablets) * dose (rapid release tablets)/AUC (rapid release tablets) * dose (sustained-release tablets) × 100%
|
Based on pre-dose, 0.25-72 hours post-dose sampling times after administration on Day 1 and Day 5
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
PK parameters of SHR0302: Tmax
Time Frame: 0 hour to 72 hour after administration with sustained-release tablets or rapid release tablets on Day 1 and Day 5
|
0 hour to 72 hour after administration with sustained-release tablets or rapid release tablets on Day 1 and Day 5
|
PK parameters of SHR0302: t1/2
Time Frame: 0 hour to 72 hour after administration with sustained-release tablets or rapid release tablets on Day 1 and Day 5
|
0 hour to 72 hour after administration with sustained-release tablets or rapid release tablets on Day 1 and Day 5
|
PK parameters of SHR0302: CL/F
Time Frame: 0 hour to 72 hour after administration with sustained-release tablets or rapid release tablets on Day 1 and Day 5
|
0 hour to 72 hour after administration with sustained-release tablets or rapid release tablets on Day 1 and Day 5
|
PK parameters of SHR0302: Vz/F
Time Frame: 0 hour to 72 hour after administration with sustained-release tablets or rapid release tablets on Day 1 and Day 5
|
0 hour to 72 hour after administration with sustained-release tablets or rapid release tablets on Day 1 and Day 5
|
Adverse events of SHR0302 with sustained-release tablets or rapid release tablets
Time Frame: from ICF signing date to day 12 (±1)
|
from ICF signing date to day 12 (±1)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 16, 2024
Primary Completion (Estimated)
March 1, 2024
Study Completion (Estimated)
May 1, 2024
Study Registration Dates
First Submitted
January 1, 2024
First Submitted That Met QC Criteria
January 1, 2024
First Posted (Actual)
January 11, 2024
Study Record Updates
Last Update Posted (Actual)
February 20, 2024
Last Update Submitted That Met QC Criteria
February 18, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHR0302-113
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autoimmune Diseases
-
SanofiRecruitingHealthy Volunteers | Autoimmune DisorderUnited States
-
National Eye Institute (NEI)Completed
-
The Eye Center and The Eye Foundation for Research...CompletedAutoimmune Polyglandular Syndrome Type I | Autoimmune Keratitis
-
Sinocelltech Ltd.Not yet recruiting
-
TakedaCompletedAutoimmune DiseaseUnited Kingdom
-
Ziv HospitalUnknownAutoimmune DiseaseIsrael
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)TerminatedAutoimmune DisordersUnited States
-
Muğla Sıtkı Koçman UniversityCompletedMultiple Sclerosis | Telerehabilitation | Autoimmune Disorder | Exercise ProgramTurkey
-
Fundación Pública Andaluza Progreso y SaludKarolinska Institutet; Eli Lilly and Company; Medical University of Vienna; Sanofi and other collaboratorsCompletedSystemic Autoimmune DiseasesFrance, Belgium, Germany, Italy, Spain, Switzerland
-
Ruijin HospitalRecruiting
Clinical Trials on SHR0302 quick release tablets
-
Jiangsu HengRui Medicine Co., Ltd.Enrolling by invitationPsoriatic ArthritisChina
-
Riphah International UniversityRecruiting
-
PfizerCompleted
-
Luye Pharma Group Ltd.Shandong Luye Pharmaceutical Co., Ltd.Completed
-
Shanghai Mental Health CenterNot yet recruiting
-
Napo Pharmaceuticals, Inc.CompletedAcquired Immunodeficiency Syndrome | HIV/AIDS | Healthy Volunteers | Human Immunodeficiency Virus | HIV DiarrheaUnited States
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruiting
-
Second Affiliated Hospital of Soochow UniversityActive, not recruitingSalivation in Parkinson's DiseaseChina
-
Overseas Pharmaceuticals, Ltd.GX pharma technology (beijing) Co., LtdActive, not recruiting
-
Jiangsu HengRui Medicine Co., Ltd.UnknownChronic Systolic Heart FailureChina